Digital biomarkers: 3PM approach revolutionizing chronic disease management — EPMA 2024 position

dc.contributor.authorSmokovski, Ivicaen
dc.contributor.authorSteinle, Nanetteen
dc.contributor.authorBehnke, Andrew J.en
dc.contributor.authorBhaskar, Sonu M. M.en
dc.contributor.authorGrech, Godfreyen
dc.contributor.authorRichter, Kneginjaen
dc.contributor.authorNiklewski, Gunteren
dc.contributor.authorBirkenbihl, Colinen
dc.contributor.authorParini, Paoloen
dc.contributor.authorAndrews, Russell J.en
dc.contributor.authorBauchner, Howarden
dc.contributor.authorGolubnitschaja, Olgaen
dc.date.accessioned2024-05-16T12:34:10Zen
dc.date.available2024-05-16T12:34:10Zen
dc.date.issued2024-05-11en
dc.description.abstractNon-communicable chronic diseases (NCDs) have become a major global health concern. They constitute the leading cause of disabilities, increased morbidity, mortality, and socio-economic disasters worldwide. Medical condition-specific digital biomarker (DB) panels have emerged as valuable tools to manage NCDs. DBs refer to the measurable and quantifiable physiological, behavioral, and environmental parameters collected for an individual through innovative digital health technologies, including wearables, smart devices, and medical sensors. By leveraging digital technologies, healthcare providers can gather real-time data and insights, enabling them to deliver more proactive and tailored interventions to individuals at risk and patients diagnosed with NCDs. Continuous monitoring of relevant health parameters through wearable devices or smartphone applications allows patients and clinicians to track the progression of NCDs in real time. With the introduction of digital biomarker monitoring (DBM), a new quality of primary and secondary healthcare is being offered with promising opportunities for health risk assessment and protection against health-to-disease transitions in vulnerable sub-populations. DBM enables healthcare providers to take the most cost-effective targeted preventive measures, to detect disease developments early, and to introduce personalized interventions. Consequently, they benefit the quality of life (QoL) of affected individuals, healthcare economy, and society at large. DBM is instrumental for the paradigm shift from reactive medical services to 3PM approach promoted by the European Association for Predictive, Preventive, and Personalized Medicine (EPMA) involving 3PM experts from 55 countries worldwide. This position manuscript consolidates multi-professional expertise in the area, demonstrating clinically relevant examples and providing the roadmap for implementing 3PM concepts facilitated through DBs.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1007/s13167-024-00364-6en
dc.identifier.orcidBehnke, Andrew [0000-0002-4970-6536]en
dc.identifier.urihttps://hdl.handle.net/10919/118997en
dc.language.isoenen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleDigital biomarkers: 3PM approach revolutionizing chronic disease management — EPMA 2024 positionen
dc.title.serialEPMA Journalen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.otherArticleen
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicineen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicine/Internal Medicineen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicine/Internal Medicine/General IMen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicine/TEACH Membersen

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
s13167-024-00364-6 (1).pdf
Size:
1.93 MB
Format:
Adobe Portable Document Format
Description:
Published version
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.5 KB
Format:
Plain Text
Description: